Loading
Sofetabart Mipitecan is an experimental antibody-drug conjugate from Eli Lilly and in phase 3 trials for ovarian cancer, aimed at Folate receptor alpha.
Sofetabart Mipitecan (LY4170156) is an antibody-drug conjugate developed by Eli Lilly and. Its target is Folate receptor alpha (the sponsor names folate receptor alpha). The sponsor states: An antibody-drug conjugate targeting folate receptor alpha that delivers a topoisomerase inhibitor payload to cancer cells. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07213804 (A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer), in ovarian cancer. The largest, NCT07213804, plans to enrol 1630 participants with primary completion expected 2028-11. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
An antibody-drug conjugate targeting folate receptor alpha that delivers a topoisomerase inhibitor payload to cancer cells. Connects to Folate receptor alpha.
1.Sofetabart Mipitecan's antibody arm binds Folate receptor alpha on the surface of the cancer cell.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Sofetabart Mipitecan" OR ABSTRACT:"Sofetabart Mipitecan" OR TITLE:"LY4170156" OR ABSTRACT:"LY4170156" OR TITLE:"Sofe-M" OR ABSTRACT:"Sofe-M") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Sofetabart Mipitecan, not a curated reading list.
Shares Folate receptor alpha, Ovarian cancer and the tag pipeline.
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Eli Lilly (incl. Loxo) and the tag pipeline.
Shares Folate receptor alpha, Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.
Shares Folate receptor alpha and the tag pipeline.
Shares Ovarian cancer and the tag pipeline.